PTGX — Recent News Coverage
All news mentioning PTGX in ESEN's AI-graded feed
News stories with PTGX as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on PTGX. See /coverage/PTGX for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-10-25
LOW
BULLISH
CORR0.42
Protagonist Therapeutics Stock: Opt-Out Turned A Biotech Royalty Compounder (NASDAQ:PTGX)
$PTGX
◈ ESEN AI
PTGX has transitioned from a conventional drug-development biotech into a royalty-compounder model, leveraging two FDA-approved therapeutics to generate recurring revenue streams. This structural pivot reduces cash-burn…
SEEKINGALPHA.COM
·
2026-08-12
HIGH
BULLISH
CORR0.72
Protagonist Therapeutics: 'Strong Buy' ICOTYDE FDA Approval And PN-881 Advancement (PTGX)
$PTGX
◈ ESEN AI
Protagonist Therapeutics (PTGX) has achieved a material catalyst with FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis. This regulatory clearance represents a thesis-changing event—the company now has a m…
SEEKINGALPHA.COM
·
2026-06-13
NEUTRAL
BULLISH
CORR0.42
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal (NASDAQ:PTGX)
$PTGX
◈ ESEN AI
Protagonist Therapeutics (PTGX) presents a clinical-stage biotech structure centered on two primary development programs with near-term FDA catalysts. The company's business model emphasizes royalty-driven revenue strea…
EXPLORE OTHER FILTERS